In early clinical trials, patients on GLP-1 agonists have achieved weight loss of 1520%, compared to the 510% typically seen with previous medications. Holistic approach to GLP-1 drugs Beyond weight loss, GLP-1 agonists have demonstrated the ability to reduce major cardiovascular events, combat fatty liver disease and alleviate obesity-related complications such as knee pain, sleep apnea, and acid reflux
Injection technique is straightforward
For controlled trials data, changes from the baseline were first measured and then mean differences [95% CI] between GLP-1-based therapy patients and controls were calculated for each study and then overall effect size of the meta-analysis was generated
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
One study of women with polycystic ovary syndrome (PCOS) and obesity treated them with semaglutide injections for 16 weeks, in addition to the diabetes drug Metformin
However, regular use over several days or weeks may be necessary for therapeutic advantages such tissue healing or inflammation reduction